Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA
Ad hoc announcement pursuant to Art. 53 LR The Phase III STEER…
AV-Comparatives Announces Outstanding Results of Cybersecurity Solutions in 2024 Endpoint Prevention and Response (EPR) Test
Download the full report here. INNSBRUCK, Austria, Dec. 11, 2024 /PRNewswire/ --…
